Receptor-mediated clearance of factor VIII: Implications for pharmacokinetic studies in individuals with haemophilia

Haemophilia

Volumn 12, Issue SUPPL. 4, 2006, Pages 15-22

  Saenko, Evgueni L ^a   Ananyeva, N M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Clearance; Factor VIII; Haemophilia; Heparan sulfate proteoglycans; Low density lipoprotein receptor related protein; Mutagenesis

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; HEPARAN SULFATE; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PROTEOGLYCAN; VON WILLEBRAND FACTOR;

BINDING AFFINITY; BINDING SITE; CELL SURFACE; DRUG CLEARANCE; DRUG HALF LIFE; EXTRACELLULAR MATRIX; HEMOPHILIA A; HUMAN; IN VIVO STUDY; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN FAMILY; PROTEIN INTERACTION; REVIEW; VON WILLEBRAND DISEASE;

EID: 33748785181     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01329.x     Document Type: Review

References (40)

1. Fay PJ. Regulation of factor VIIIa in the intrinsic factor Xase. Thromb Haemost 1999; 82: 193-200.
2. Saenko EL, Ananyeva NM, Tuddenham EG, Kemball-Cook G. Factor VIII -novel insights into form and function. Br J Haematol 2002; 119: 323-31.
3. Saenko EL, Scandella D. The acidic region of the light chain and the C2 domain together form a high affinity binding site for von Willebrand factor. J Biol Chem 1997; 272: 18007-14.
4. Lenting PJ, van de Loo JW, Donath MJ, van Mourik JA, Mertens K. The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX. J Biol Chem 1996; 271: 1935-40.
5. Fay PJ, Koshibu K. The A2 subunit of factor VIIIa modulates the active site of factor IXa. J Biol Chem 1998; 273: 19049-54.
6. Fay PJ, Scandella D. Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa. J Biol Chem 1999; 274: 29826-30.
7. Saenko EL, Yakhyaev AV, Mikhailenko I, Strickland DK, Sarafanov AG. Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism. J Biol Chem 1999; 274: 37685-92.
8. Lenting P, Neels JG, van den Berg BM et al. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein. J Biol Chem 1999; 274: 23734-9.
9. Schwarz HP, Lenting PJ, Binder B et al. Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von Willebrand factor-deficient mice. Blood 2000; 95: 1703-8.
10. Turecek PL, Lenting PJ, van Mourik JA et al. Low density lipoprotein receptor-related protein (LRP) mediates the clearance of factor VIII in vWf-deficient mice. Blood 1999; 94: 647a.
11. Turecek PL, Schwarz HP, Binder BR. In vivo inhibition of low density lipoprotein receptor-related protein improves survival of factor VIII in the absence of von Willebrand factor. Blood 2000; 95: 3637-8.
12. Neels JG, Horn IR, Van den Berg BMM, Pannekoek H, van Zonneveld A-J. Ligand-receptor interactions of the low density lipoprotein receptor-related protein, a multi-ligand endocytic receptor. Fibrinolysis Proteolysis 1998; 12: 219-40.
13. Sarafanov AG, Ananyeva NM, Shima M, Saenko EL. Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein. J Biol Chem 2001; 276: 11970-9.
14. Bovenschen N, Herz J, Grimbergen JM et al. Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency. Blood 2003; 101: 3933-9.
15. Hollestelle MJ, Geertzen HG, Straatsburg IH, van Gulik TM, van Mourik JA. Factor VIII expression in liver disease. Thromb Haemost 2004; 91: 267-75.
16. Bovenschen N, Mertens K, Hu L, Havekes LM, van Vlijmen BJ. LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo. Blood 2005; 106: 906-12.
17. Kouiavskaia DV, Ruiz JF, Strickand DK, Saenko EL. Very low density lipoprotein receptor interacts with coagulation factor VIII. Blood 2003; 102: 88a.
18. Mertens K, Bovenschen N, Voorberg J, Meijer AB. The endocytic receptors megalin and low-density lipoprotein receptor-related protein share binding to coagulation factor VIII. Blood 2003; 102: 89a.
19. Makogonenko E, Sarafanov A, Pechik I et al. The A2 domain of coagulation factor VIII shares residues critical for interaction with three members of LDL receptor superfamily - LRP, VLDL and megalin receptors. J Thromb Haemost 2005; 3 (Suppl. 1): P0646.
20. Bovenschen N, van Dijk KW, Havekes LM, Mertens K, van Vlijmen BJ. Clearance of coagulation factor VIII in very low-density lipoprotein receptor knockout mice. Br J Haematol 2004; 126: 722-5.
21. Bovenschen N, Boertjes RC, van Stempvoort G et al. Low density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII. J Biol Chem 2003; 278: 9370-7.
22. Stoilova-McPhie S, Villoutreix BO, Mertens K, Kemball-Cook G, Holzenburg A. Three-dimentional structure of membrane-bound coagulation factor VIII: Modeling of the factor VIII heterodimer within a three-dimentional density map derived by electron crystallography. Blood 2002; 99: 1215-23.
23. Sarafanov A, Makogonenko E, Radtke K-P et al. Identification of factor VIII A2 domain residues forming the binding epitope for low-density lipoprotein receptor-related protein. J Thromb Haemost 2005; 3 (Suppl. 1): P1840.
24. Lethagen S, Berntorp E, Nilsson IM. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III. Ann Hematol 1992; 65: 253-9.
25. 125 iodine-labeled factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human factor VIII. J Clin Invest 1978; 62: 223-34.
26. Fijnvandraat K, Berntorp E, Ten Cate JW et al. Recombinant,B-domain deleted factor VIII (r-VIII SQ): Pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb Haemost 1997; 77: 298-302.
27. Fijnvandraat K, Peters M, Ten Cate JW. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br J Haematol 1995; 91: 474-6.
28. van Dijk K, van der Bom JG, Lenting PJ et al. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica 2005; 90: 494-8.
29. Vlot AJ, Mauser-Bunschoten EP, Zarkova AG et al. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. Thromb Haemost 2000; 83: 65-9.
30. Bjorkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001; 40: 815-32.
31. Bovenschen N, van Stempvoort G, Voorberg J, Mertens K, Meijer AB. Cleavage of factor VIII heavy chain by thrombin increases the affinity for low-density lipoprotein receptor-related protein (LRP). J Thromb Haemost 2003; Suppl July: OC095.
32. Neels JG, Bovenschen N, Zonneveld A-J, Lenting P. Interaction between factor VIII and LDL receptor-related protein. Trends Cardiovasc Med 2000; 10: 8-14.
33. Herz J, Strickland DK. LRP: A multifunctional scavenger and signaling receptor. J Clin Invest 2001; 108: 779-84.
34. Neels JG, Berg BMM, Looken A, Olivecrona G, Pannekoek H, Zonneveld A-J. The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties. J Biol Chem 1999; 274: 31305-11.
35. Sarafanov A, Makogonenko E, Andersen O et al. Identification of regions in low-density lipoprotein receptor-related protein responsible for interaction with A2 and A1/A3-C1-C2 portions of coagulation factor VIII. J Thromb Haemost 2005; 3 (Suppl. 1): OR248.
36. Morange PE, Tregouet DA, Frere C et al. Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort. Br J Haematol 2005; 128: 91-9.
37. Cunningham N, Laffan MA, Manning RA, O'Donnell JS. Low-density lipoprotein receptor-related protein polymorphisms in patients with elevated factor VIII coagulant activity and venous thrombosis. Blood Coagul Fibrinolysis 2005; 16: 465-8.
38. Ananyeva N, Khrenov A, Darr F, Summers R, Sarafanov A, Saenko E. Treating haemophilia A with recombinant blood factors: A comparison. Expert Opin Pharmacother 2004; 5: 1061-70.
39. Ananyeva NM, Lacroix-Desmazes S, Hauser CA et al. Inhibitors in hemophilia A: Mechanisms of inhibition, management and perspectives. Blood Coagul Fibrinolysis 2004; 15: 109-24.
40. Parker ET, Healey JF, Barrow RT, Craddock HN, Lollar P. Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope. Blood 2004; 104: 704-10.